Am Fam Physician. 2004 Feb 15;69(4):947-948.
The high rate of preterm delivery in the United States is the greatest contributor to the relatively high infant mortality rate in this country. Despite much effort, no effective method exists for prevention of preterm delivery. Progesterone has been studied as a prophylactic agent for preterm delivery with conflicting results. A meta-analysis of older trials using only 17 alpha-hydroxyprogesterone (17P) showed a significant protective effect. Meis and colleagues designed a multicenter modern retrial of 17P for prevention of pre-term delivery.
The authors screened patients for enrollment by reviewing prenatal charts of pregnancies at 15 to 20 weeks of gestation for a history of preterm delivery. Initial screening identified 2,980 women, of whom 1,039 were eligible after exclusion criteria, which included lack of documentation for prior preterm delivery, ultrasound dating of more than 20 weeks' gestation, planned cerclage, multifetal pregnancy, or prior progesterone use during the current pregnancy. After informed consent, 463 women (45 percent) agreed to participate in the trial. Fifty-nine percent were black, 26 percent were white, 14 percent were Hispanic, and 1 percent were from other groups. Almost one half of the enrolled women had a history of more than one preterm delivery. Outcome data were available for 99 percent of the pregnancies.
Spontaneous preterm delivery before 37 weeks' gestation among patients receiving placebo injections occurred in 45.1 percent but declined to 29.4 percent with 17P supplementation. The rate of preterm deliveries at less than 32 weeks' gestation was cut almost in half by treatment (19.6 percent of control pregnancies versus 11.4 percent of the 17P group). The reduction in preterm deliveries was similar across ethnic groups. The progesterone group showed significant reductions in birth weights below 2,500 g (5 lb 5 oz), necrotizing enterocolitis, and intraventricular hemorrhage. There were no apparent adverse effects to the prolongation of pregnancy achieved with 17P supplementation. Rates of chorioamnionitis and neonatal sepsis were similar between control and treatment groups.
The authors conclude that weekly injections of 17P reduced the rate of preterm delivery and decreased neonatal morbidity when used in women with a history of preterm delivery.
Meis PJ, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. June 12, 2003;348:2379–85.
editor's note: Medical history is replete with theoretically sound and well-intentioned treatments for preterm delivery that have, in the end, not changed outcomes significantly. An accompanying editorial by Greene1 notes that the “generalizability” of the Weis study results may be limited by the very-high-risk population studied (over one half of control subjects delivered preterm) and the existence of several other earlier (albeit smaller) studies of 17P supplementation that have shown inconsistent results. The American College of Obstetricians and Gynecologists (ACOG) recently released a committee opinion2 referencing this and one other study of progesterone supplementation for prevention of preterm delivery. Given the limited data, ACOG recommends restricting any consideration of the use of progesterone supplementation to women with a history of delivery before 37 weeks of gestation. Use in women with other risk factors for preterm delivery (e.g., multifetal gestations, shortened cervical length, or positive fetal fibronectin testing) is not recommended at present.—b.z.
1. Greene MF. Progesterone and preterm delivery—déjà vu all over again. [Editorial]. N Engl J Med. 2003;348:2453–5.
2. American College of Obstetricians and Gynecologists Committee on Obstetric Practice. Use of progesterone to reduce preterm birth. ACOG committee opinion no. 291. Obstet Gynecol. 2003;102:1115–6.
Copyright © 2004 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions